Corrêa Luisa Queiroz, do Couto Bruna Patrícia, de Carvalho Edson Fernando Goulart, de Sousa José Eduardo Neto, da Silva Ribeiro Vanessa, Gonzaga Henrique Tomaz, Costa-Cruz Julia Maria
Laboratório de Diagnóstico de Parasitoses, Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais Brazil.
J Parasit Dis. 2023 Sep;47(3):520-526. doi: 10.1007/s12639-023-01595-6. Epub 2023 May 18.
Rodents infected with are experimental models applied to strongyloidiasis research. This study evaluated oral and subcutaneous dexamethasone (DEX) treatments to establish immunosuppression in an experimental model of hyperinfection. Wistar were divided: G I (-): untreated and uninfected animals, G II (+): untreated and infected, G III (o -) orally treated and uninfected, G IV (o +) orally treated and infected, G V (sc -) subcutaneously treated and uninfected, G VI (sc +) subcutaneously treated and infected. For oral administration, DEX was diluted in sterile water (5 µg/ml) and made available to the animals on intervals in experimental days - 5-0, 8-13 and 21-26. For subcutaneous administration, animals received daily injections of DEX disodium phosphate (2 mg/kg). Infection was established by the subcutaneous inoculation of 3000 filarioid larvae. Groups were evaluated by egg per gram of feces and parasite females counts and IgG, IgG1 and IgG2a detection. GIV (o +) had egg peaks count on days 13 and 26 and maintained egg elimination until the last experimental day. Parasitic females recovery at day 30 was significantly higher in G IV (o +) when compared to G VI (sc +). Levels of IgG, IgG1 and IgG2a of all groups, except the positive control GII (+), were below the detection threshold. Pharmacological immunosuppression induced by oral administration of DEX produced high parasitic burden, and is a noninvasive method, useful to establish immunosuppression in strongyloidiasis hyperinfection model in rats.
感染[具体寄生虫名称未给出]的啮齿动物是用于类圆线虫病研究的实验模型。本研究评估了口服和皮下注射地塞米松(DEX)治疗,以在[具体寄生虫名称未给出]超感染实验模型中建立免疫抑制。将Wistar大鼠分为:第一组(-):未治疗且未感染的动物;第二组(+):未治疗且感染的动物;第三组(o -):口服治疗且未感染的动物;第四组(o +):口服治疗且感染的动物;第五组(sc -):皮下治疗且未感染的动物;第六组(sc +):皮下治疗且感染的动物。对于口服给药,DEX用无菌水(5微克/毫升)稀释,并在实验第-5至0天、8至13天和21至26天期间供动物使用。对于皮下给药,动物每日注射磷酸地塞米松二钠(2毫克/千克)。通过皮下接种3000条丝状蚴建立感染。通过每克粪便中的虫卵计数、寄生虫雌虫计数以及检测IgG、IgG1和IgG2a对各组进行评估。第四组(o +)在第13天和26天出现虫卵峰值计数,并在最后一个实验日之前持续有虫卵排出。与第六组(sc +)相比,第四组(o +)在第30天的寄生雌虫回收率显著更高。除阳性对照组第二组(+)外,所有组的IgG、IgG1和IgG2a水平均低于检测阈值。口服DEX诱导的药理学免疫抑制导致高寄生虫负荷,并且是一种非侵入性方法,有助于在大鼠类圆线虫病超感染模型中建立免疫抑制。